TLM-005 by Therillume for Glioblastoma Multiforme (GBM): Likelihood of Approval
TLM-005 is under clinical development by Therillume and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData's report assesses how TLM-005's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.TLM-005 overviewTLM-005 is under development for the treatment of glioblastoma (GBM). The drug candidate is developed using Therillume platform which is a gene-editing technology. Therillume overviewTherillume is a clinical stage company that develops neuro-oncology therapeutics and offers precision medicines used for the treatment of glioblastoma and neurofibromatosis. The company is headquartered in Eagan, Minnesota, the US. For a complete picture of TLM-005's drug-specific PTSR and LoA scores, buy the report here.
TLM-005 is under clinical development by Therillume and currently in Phase I for Glioblastoma Multiforme (GBM).
What's Your Reaction?
